Cargando...
Chimeric antigen receptor T cells engineered to secrete CD40 agonist antibodies enhance antitumor efficacy
BACKGROUND: Although chimeric antigen receptor (CAR)-T cell therapy has been remarkably successful for haematological malignancies, its efficacy against solid tumors is limited. The combination of CAR-T cell therapy with immune checkpoint inhibitors (CPIs), such as PD-1, PD-L1, and CTLA-4 antibodies...
Guardado en:
| Publicado en: | J Transl Med |
|---|---|
| Autores principales: | , , , , , |
| Formato: | Artigo |
| Lenguaje: | Inglês |
| Publicado: |
BioMed Central
2021
|
| Materias: | |
| Acceso en línea: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7890961/ https://ncbi.nlm.nih.gov/pubmed/33602263 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12967-021-02750-4 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|